In context, the honest answer is no: lithium is not shown to reverse Alzheimer's in people. A 2025 mouse study restored lithium (as orotate) and prevented pathology, and observational data link higher lifelong exposure to lower dementia risk — but animal and population findings establish plausibility, not human treatment, and the first randomized trial in people did not meet its goals.
Does any study show lithium reversing Alzheimer's in people?
No human study demonstrates reversal of Alzheimer's with lithium. The human population literature is observational and concerns risk — associations between higher lifelong trace-lithium exposure and lower dementia rates — not reversal of established disease. The largest, a Danish nested case-control analysis by Kessing and colleagues (2017; 73,731 dementia cases), found a non-linear association with dementia incidence (DOI). That is about who develops dementia, not about reversing it once present. For the wider picture, see lithium and dementia.
What did the 2025 lithium study actually show?
The 2025 study (Aron and colleagues, Nature) reported that amyloid plaques sequester lithium, lowering its bioavailability in the Alzheimer's brain, and that depleting lithium in mice increased amyloid and phospho-tau while restoring lithium with lithium orotate — a salt the authors selected because it showed reduced amyloid binding — prevented pathology and memory loss in Alzheimer's mouse models and ageing wild-type mice, mediated in part through the enzyme GSK-3β (DOI). These are animal and human-tissue findings. They describe a proposed mechanism and biological plausibility, not human treatment or reversal. The accompanying Nature commentary by Bush (2025) framed the deficiency idea as an important but unproven hypothesis (DOI).
Is it proven in humans?
Not yet, and the most important recent result needs to be read carefully. The first randomized trial of low-dose lithium in mild cognitive impairment (Gildengers 2026, JAMA Neurology; 80 adults, two years) did not meet its primary outcomes, with only a borderline signal on one verbal-memory measure (DOI). Notably, that trial used lithium carbonate — the form that, under the leading 2025 hypothesis, is sequestered by amyloid in the Alzheimer's brain. So the result tempers certainty about low-dose lithium, but it does not test, or rule out, the non-sequestered forms (such as the orotate used in the mouse work). It is not evidence that "lithium failed in humans."
Earlier, smaller studies were more encouraging: a placebo-controlled trial in amnestic mild cognitive impairment reported slowed decline and reduced tau phosphorylation (reviewed by Forlenza and colleagues, 2012; DOI), and a microdose study reported stabilized cognition in Alzheimer's patients (Nunes and colleagues, 2013; DOI). These are small early signals, not demonstrations of treatment efficacy or reversal. A 2026 narrative review in JAMA Psychiatry (Moore and colleagues) places this within 25 years of work on lithium as a possible disease-modifying agent and notes the "repletion hypothesis" still awaits independent replication (DOI). See the full studies database, by form.
Why don't mouse results mean lithium reverses human Alzheimer's?
Animal findings are among the weaker forms of evidence for human benefit, and many interventions that change markers in mice fail in human trials. Several factors limit translation:
| Factor | Why it limits translation |
|---|---|
| Species differences | Mouse metabolism, lifespan, and brain biology differ from humans |
| Dose translation | Doses effective in rodents do not necessarily map to humans |
| Model limitations | Mouse models reproduce some, but not all, features of human Alzheimer's |
| Markers vs outcomes | Changing biomarkers in mice is not the same as restoring human cognition |
For more on the proposed biology, see how lithium works in the brain.
Limitations and safety
No human data support reversing Alzheimer's with lithium, and no health authority recommends lithium for this purpose. Prescription lithium is a medication with serious risks that requires clinical monitoring, and the long-term safety of low-dose supplemental lithium is not well characterized. None of this research supports self-treating with lithium in any form. This article is educational and is not medical advice. For the full picture across forms and doses, see lithium and the brain.
Frequently asked questions
Can lithium cure or reverse Alzheimer's?
No. There is no human evidence that lithium cures or reverses Alzheimer's. Observational studies concern dementia risk, not reversal, and the 2025 findings (Aron and colleagues, Nature) are from mouse models and human tissue. Reversal is not an established outcome of lithium in people.
Is lithium a treatment for Alzheimer's?
Lithium is not an approved or established treatment for Alzheimer's disease. The first randomized trial of low-dose lithium in mild cognitive impairment (2026) did not meet its primary outcomes, and earlier small trials were encouraging but do not establish treatment efficacy.
Did the 2026 lithium trial show it does not work?
It is more specific than that. The 2026 trial used lithium carbonate, the form thought to be bound up by amyloid in the Alzheimer's brain, and missed its primary outcomes with only a borderline memory signal. That tempers certainty about low-dose lithium, but it does not test the non-sequestered forms (such as orotate) used in the mouse work, and it is not evidence that lithium failed in humans.
Why isn't promising mouse data enough?
Animal results establish biological plausibility, but many interventions that change markers in mice fail in human trials due to species, dose, and model differences. Demonstrating an effect in mice is a research starting point, not evidence that lithium reverses Alzheimer's in people.